Ligand Pharmaceuticalshas earned a $500,000 milestone payment from SAGE Therapeutics relating to the initiation of SAGE’s Phase III study to evaluate the safety of SAGE-547 in patients with super-refractory status epilepticus (SRSE).   Results from this trial, along with results from SAGE’s planned Phase III placebo-controlled trial, and other clinical data from the SAGE-547 development program will be used for an New Drug Application (NDA) submission.    Ligand entered into a Captisol lic...